Cardiovascular Disease and Outcomes Among Patients With SARS-CoV-2 Infection (COVID-19)

Overseen by Kate Hanneman

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University Health Network, Toronto

No Placebo Group

Trial Summary

What is the purpose of this trial?

The coronavirus disease of 2019 (COVID-19) has affected over 2.4 million individuals worldwide and has resulted in \>171,000 deaths. Cardiovascular disease (CVD) is an important contributor to death in these patients. Those who develop cardiac injury during infection have a 4-fold increased risk of death. Furthermore, pre-existing CVD or cardiovascular risk factors (e.g. diabetes, hypertension) are associated with worse outcomes. Given the recent emergence of this disease, there is limited understanding of: (i) the risk factors for cardiovascular events, (ii) blood biomarkers for early recognition, and drug targeting, of patients at risk of adverse outcomes, and (iii) the short term subclinical and clinical cardiovascular manifestations in those who survive to discharge.

Research Team

Dinesh Thavendiranathan

Principal Investigator

University Health Network, Toronto

Kathryn Howe

Principal Investigator

University Health Network, Toronto

Kate Hanneman

Principal Investigator

University Health Network, Toronto

Eligibility Criteria

Inclusion Criteria

COVID-19+ confirmed by RT-PCR (Reverse Transcriptase - Polymerase Chain Reaction).

Age ≥ 18 years.

Treatment Details

Interventions

• Bloodwork (Diagnostic Test)
• Echocardiogram (Diagnostic Test)
• MRI (Diagnostic Test)
• PET/MRI (Diagnostic Test)

Participant Groups

Group I: Severe Disease Experimental Treatment 1 Intervention

Those requiring admission to ICU or other advanced care settings (i.e. other Level 2 beds)

Group II: Moderate Disease Experimental Treatment 1 Intervention

Those admitted but never requiring transfer to ICU or similar advanced care setting

Group III: Mild Disease Experimental Treatment 1 Intervention

Those assessed as an outpatient or discharged from the emergency department and never admitted elsewhere based on patient history

Group IV: Control Group Experimental Treatment 1 Intervention

Those with a negative COVID-19 and no history of COVID-19

Who Is Running the Clinical Trial?

University Health Network, Toronto

Lead Sponsor

Trials

1,555

Recruited

526,000+

Dr. Brad Wouters

University Health Network, Toronto

Chief Medical Officer since 2020

MD from University of Toronto

Dr. Kevin Smith

University Health Network, Toronto

Chief Executive Officer since 2018

Professor at McMaster University and University of Toronto